Table 3.
Hemagglutination-inhibition (HAI) | Geometric Mean Titer (GMT) ± Standard Error of the Mean (SEM) | Seroprotection at D0 & D21 + Seroconversion (SC) Rates.
| Vaccine Season |
YAMAGATA LINEAGE |
VICTORIA LINEAGE |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014–2015 (n = 277) |
B/Massachusetts/02/2012 |
B/Brisbane/60/2008 (excluded from the vaccine) |
|||||||||||
| Age (y.o.) | n-value | D0 | D21 | Fold Rise | D0 ≥ 40 | D21 ≥ 40 | SC | D0 | D21 | Fold Rise | D0 ≥ 40 | D21 ≥ 40 | SC |
| 18–34 | 44 | 249 ± 72 | 505 ± 133 | 2.03 | 98% | 100% | 18% | 43 ± 29 | 137 ± 61 | 3.21 | 66% | 100% | * 39% |
| 35–49 | 38 | 124 ± 40 | 257 ± 41 | 2.07 | 95% | 100% | 16% | 54 ± 22 | 133 ± 41 | 2.49 | 74% | 92% | * 34% |
| 50–64 | 102 | 92 ± 11 | 217 ± 34 | 2.37 | 86% | 100% | 32% | 35 ± 6 | 85 ± 16 | 2.45 | 56% | 86% | * 36% |
| 65–85 (SD) | 54 | 80 ± 12 | 182 ± 32 | 2.27 | 83% | 98% | 30% | 26 ± 8 | 47 ± 10 | 1.83 | 43% | 63% | * 19% |
| 65–85 (HD) |
39 |
86 ± 19 |
216 ± 37 |
2.52 |
87% |
100% |
36% |
17 ± 9 |
27 ± 12 |
1.59 |
36% |
46% |
* 15% |
| 2015–2016 (n = 267) |
B/Phuket/3073/2013 |
B/Brisbane/60/2008 (excluded in HD formulation) |
|||||||||||
| Age (y.o.) |
n-value |
D0 |
D21 |
Fold Rise |
D0 ≥ 40 |
D21 ≥ 40 |
SC |
D0 |
D21 |
Fold Rise |
D0 ≥ 40 |
D21 ≥ 40 |
SC |
| 18–34 | 48 | 135 ± 34 | 298 ± 44 | 2.21 | 88% | 96% | 23% | 45 ± 6 | 113 ± 16 | 2.52 | 71% | 100% | 31% |
| 35–49 | 39 | 58 ± 20 | 188 ± 48 | 3.23 | 69% | 97% | 44% | 51 ± 8 | 141 ± 23 | 2.75 | 77% | 97% | 36% |
| 50–64 | 82 | 49 ± 11 | 137 ± 23 | 2.83 | 67% | 94% | 45% | 56 ± 6 | 118 ± 13 | 2.12 | 78% | 94% | 28% |
| 65–85 (SD) | 40 | 37 ± 11 | 117 ± 38 | 3.19 | 58% | 98% | 43% | 31 ± 7 | 62 ± 12 | 2.00 | 55% | 83% | 28% |
| 65–85 (HD) |
58 |
50 ± 11 |
149 ± 21 |
3.00 |
76% |
97% |
53% |
27 ± 8 |
51 ± 12 |
1.91 |
41% |
67% |
* 21% |
| 2016–2017 (n = 257) |
B/Phuket/3073/2013 (excluded in HD formulation) |
B/Brisbane/60/2008 |
|||||||||||
| Age (y.o.) |
n-value |
D0 |
D21 |
Fold Rise |
D0 ≥ 40 |
D21 ≥ 40 |
SC |
D0 |
D21 |
Fold Rise |
D0 ≥ 40 |
D21 ≥ 40 |
SC |
| 18–34 | 39 | 114 ± 27 | 216 ± 43 | 1.90 | 92% | 97% | 13% | 45 ± 7 | 79 ± 11 | 1.77 | 74% | 95% | 13% |
| 35–49 | 36 | 53 ± 72 | 125 ± 71 | 2.33 | 67% | 97% | 31% | 63 ± 26 | 92 ± 24 | 1.44 | 81% | 97% | 8% |
| 50–64 | 86 | 56 ± 11 | 104 ± 13 | 1.85 | 71% | 87% | 24% | 50 ± 10 | 77 ± 13 | 1.55 | 77% | 88% | 10% |
| 65–85 (SD) | 22 | 28 ± 28 | 85 ± 60 | 3.01 | 50% | 82% | 50% | 26 ± 29 | 64 ± 16 | 2.49 | 50% | 77% | 32% |
| 65–85 (HD) | 74 | 45 ± 10 | 70 ± 22 | 1.57 | 65% | 76% | * 15% | 24 ± 7 | 66 ± 15 | 2.75 | 43% | 80% | 42% |
*seroconversion due to cross-boosting and other effects since this strain wasn’t included in the vaccine for this group (2014–2015 season lacked the Victoria-lineage component altogether, but the WHO-recommended strain was used for analysis)